NASDAQ · FEED

ENvue Medical, Inc.

$0.38 -$0.00 (-0.57%) 1D After hours

Key Metrics

$2.34M
Market cap
P/E · TTM
$2.18M
Revenue · TTM
−$19.51M
Net income
EPS · TTM $-311.62
Dividend yield
Free cash flow −$12.41M
Beta · 1Y 0.57
EBITDA · TTM −$18.71M
Gross margin -12.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    From its Jan 29 high, the share price fell 91%.

    Peak close $3.84 on Jan 29; trough close $0.36 on Jul 21. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -91%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 24
    The stock moved +58.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 24
  • Feb 4
    The stock moved +26.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.34M
Enterprise value
Shares outstanding6.1M
52-wk range$0.35 – $6.09
Avg volume · 20D5.5M
Net cash
Book value / share$511.30
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNASDAQ
About ENvue Medical, Inc.
IPO dateApr 24, 2015
Employees14

ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.07
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross -12.4%
Operating -907.9%
Net -894.6%
FCF -569.1%
ROE / ROIC -119.6% · -65.5%

Financial Health

Current ratio0.90
Quick ratio0.57
Debt / equity
Debt / EBITDA
Net cash
Working capital−$668.00K

Cash Flow · TTM

Operating CF −$12.34M
Capex −$72.00K
Free cash flow −$12.41M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-5.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings